Is Evexia Lifecare overvalued or undervalued?

As of 14 October 2025, Evexia Lifecare's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on its current financial metrics. The PE ratio stands at an extraordinarily high 214.55, while the EV to EBITDA ratio is also elevated at 207.60, suggesting that the stock is priced significantly above its earnings potential. In contrast, the Price to Book Value ratio is more reasonable at 0.86, but overall, the high multiples indicate a lack of justification for the current price.
When compared to peers, Evexia Lifecare's valuation metrics starkly contrast with companies like Castrol India, which has a PE ratio of 20.55 and an EV to EBITDA of 14.30, and Gulf Oil Lubricants, with a PE of 16.18 and an EV to EBITDA of 11.01. These comparisons highlight that Evexia Lifecare is trading at a premium relative to its industry peers. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -42.03% compared to the Sensex's 4.98%. This further reinforces the conclusion that Evexia Lifecare is overvalued in the current market environment.